Market Access Indication-specific pricing in England: Business as usual? Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.
Market Access Missing metrics on the UK’s VPAG It's hard to take stock of what’s happening operationally with the UK's main pricing scheme, VPAG, given the absence of reporting by the DHSC.
Market Access FT Summit: How Is U.S. Policy Reshaping the UK and EU Pharma... For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.
Views & Analysis 'Free' pricing in the UK: the influence of NICE and NHS Engl... UK drug pricing: just how free is free pricing, these days?
News Danco fights back after US court curbs abortion pill access In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.